RhoVac participates in international business conferences in the UK and the United States
RhoVac AB ("RhoVac") will participate in J.P. Morgan Healthcare Conference in San Francisco, USA in January 2019 and at the Jefferies London Healthcare Conference, UK, 14-15 November 2018.
From 7th to 10th January 2019, RhoVac will attend J.P. Morgan Healthcare Conference in San Francisco, USA and in connection with the conference, RhoVac's CEO Anders Ljungqvist will present at the Biotech Showcase. The annual recurring conference, which is the largest of its kind, brings together more than 10,000 corporate representatives from the pharmaceutical industry, investment and finance and service sectors from more than 450 companies and academic institutions.
RhoVac are attending Jefferies London Healthcare Conference from 14th to 15th November 2018, organized in collaboration with Jeffrerie's Investment Bank. At the London conference, 350 companies and more than 1,400 participants attend, and RhoVac is there to have individual meetings with potential partners.
For more information, please contact:
Anders Ljungqvist – CEO, RhoVac AB
Phone: +45 4083 2365
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's top-line results from the clinical phase I / II study has been published I August 2018. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Trade Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.